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indicate that single-agent chemotherapy could be the preferred option 
in the treatment of PS 2 patients, with carboplatin-based or low-dose 
cisplatin-based doublets representing alternative options .To date 
randomised trial in USA (carboplatin+ gemcitabine vs gemcitabine) 
and in Italy (cisplatin+gemcitabine vs gemcitabine) are ongoing. In 
the near future, the role of targeted agents with better safety proﬁle 
than chemotherapy as the EGFR-TKI erlotinib, has to be explored in 
the ﬁrst-line treatment of advanced NSCLC PS2 patients . Non small 
cell lung cancer (NSCLC) may be considered typical of advanced 
age. More than 50% of lung cancer patients are diagnosed over the 
age of 65 and about 30% over the age of 70. More than two-thirds of 
patients dying of lung cancer in the United States are over 65 years old. 
Elderly patients tolerate chemotherapy poorly because of comorbid-
ity and organ failure. Prospective phase II trials have demonstrated 
suitable toxicity proﬁle and good antitumor activity for single agent 
chemotherapy with vinorelbine, gemcitabine and taxanes in the treat-
ment of advanced NSCLC elderly patients. Vinorelbine, in a phase 
III randomized trial named ELVIS (Elderly Lung Cancer Vinorelbine 
Italian Study), compared to best supportive care, has proven to improve 
survival and quality of life of advanced NSCLC patients. In order to 
improve results obtained with monochemotherapy, the development of 
non cisplatin-based combinations is an interesting issue in the treatment 
of advanced NSCLC elderly patients. In fact the possibility of having 
active and well-tolerated chemotherapy while preserving patient quality 
of life is more attractive in the elderly. The most studied non platin-
based regimen is the combination of gemcitabine plus vinorelbine, 
resulted active and well-tolerated in several phase II trials. However, 
a large phase III randomized trial (MILES-Multicenter Italian Lung 
cancer in the Elderly Study), enrolling about 700 patients, showed that 
polychemotherapy with gemcitabine and vinorelbine does not improve 
any outcome (response rate, time to progression, survival or quality 
of life) as compared to single agent chemotherapy with vinorelbine or 
gemcitabine. In clinical practice, single agent chemotherapy should 
remain the standard treatment. Feasibility of cisplatin-based polyche-
motherapy remains an open issue and has been recently addressed by 
some retrospective analyses of randomized trials without age limits, 
suggesting that advanced age alone should not preclude aggressive 
cisplatin-based treatment to ﬁt NSCLC elderly patients. The evidences 
from these analyses could however suffer from selection bias, because 
their target population may not be representative of the whole elderly 
population but only of a small subgroup thought to be eligible for 
aggressive treatments by investigators. Prospective clinical trials with 
inclusion criteria selective for elderly population are to be considered 
the unique tool for investigating cisplatin-based chemotherapy in this 
clinical setting. More recently some prospective phase II trials have ex-
plored innovative schedules of cisplatin delivering that could be more 
suitable to elderly population . 
Among new biologic agents, the Epidermal Growth Factor Receptor ty-
rosine-kinase inhibitor erlotinib, characterized by a favourable toxicity 
proﬁle, potentially suitable to elderly population, is being investigated. 
Erlotinib has been tested as ﬁrst-line treatment in unselected elderly 
patients showing good tolerability and activity with 11% response rate 
and a median survival of 10.5 months. Among antiangigenetic agents 
ZD1271 seems be of interest in the elderly. Drugs with multiple target 
are the new frontiers of biologic therapy. ZD6474, a small molecule 
that inhibits VEGF and EGFR, and sorafenib , with VEGF , PDGF and 
c-kit as target, merit to be investigated in elderly NSCLC patients. 
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Staging of the intrathoracic mediastinal and pulmonary lymph nodes is 
one of the most important problems in the treatment of non-small cell 
lung cancer. The map of the mediastinal and pulmonary lymph nodes 
proposed by Clifton F. Mountain and Carolyn M. Dresler gained wide 
acceptance and has become a standard of staging. However, it has some 
shortcomings of clarity in the description of localization of speciﬁc 
nodal stations. In our opinion, some modiﬁcations of this map are 
necessary. Based on our experience with extended mediastinoscopy and 
the new procedure, transcervical extended mediastinal lympadenec-
tomy, the main changes we propose are: 1) the left innominate vein as 
the anatomic separation between nodal stations 1 and 2; 2) the merging 
of station 2 and 4 in a single right and left paratracheal station; 3) the 
shift of the midline to the left paratracheal margin; 4) the tracheobron-
chial angles as the landmark between stations 4 and 10 bilaterally; 5) 
the separation of three nodal groups in the subcarinal area: subcarinal 
(number 7), peribronchial (number 10R and 10L), and periesophageal 
(number 8); 6) the merging of station 5 and station 6 nodes in a single 
station with the following landmarks: medial border: the midline, 
lateral border, the descending aorta and upper border: the left innomi-
nate vein and lower border: the lower margin of the left pulmonary 
artery; and 7) the deﬁnition of station 3A nodes as those in front of the 
superior vena cava.
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Introduction
Despite improvements in early diagnosis and treatment, the vast major-
ity-85%- of patients with lung cancer will ultimately die from their 
disease and most of them within 1 year of diagnosis. Physicians caring 
for patients with lung cancer should hence be aware of the prevailing 
symptoms in the advanced stage and acquire the expertise to cope with 
these. 
The British Medical Research Council reported on patient’s selfreport-
ed symptoms were similar in NSCLC and SCLC and came from a vari-
ety of domains: psychological (worrying and anxious feelings), general 
(tiredness, lack of energy, lack of appetite and difﬁculty sleeping) and 
chest symptoms (shortness of breath and cough) [Hopwood 1995]. The 
symptoms most frequently reported as severe were: decreased sexual 
interest, lack of energy and dyspnea.The number of symptoms reported 
was on average 17.4 for SCLC and 14.3 for NSCLC and increased with 
worsening performance status. An effect of gender was not clear. In the 
course of illness, most symptoms tend to recur or increase in number 
and severity. 
This article will focus on the evidence-based comprehensive manage-
ment of 4 symptoms speciﬁc to patients with lung cancer: dyspnea, 
cough, hemoptysis, anorexia/cachexia and fatigue. This review 
deliberately excludes chemo- and radiotherapy, invasive interventions 
and the management of pain, as these are dealt with in a number of 
